Related Experiment Video
Updated: Mar 30, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis
P Gisondi1, E Barba1, G Girolomoni1
1Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
Background:
Patients with psoriasis are at risk of non-alcoholic fatty liver disease (NAFLD) and likely liver fibrosis.
Objective:
Investigate the prevalence of NAFLD in patients with psoriasis and measure their risk of liver fibrosis.
Method:
One hundred and twenty-four patients with psoriasis and 79 healthy controls were included in this cross-sectional study. NAFLD was diagnosed in the presence of characteristic sonographic features of fatty liver after excluding other secondary causes of chronic liver disease. NAFLD fibrosis score (NAFLD-FS) was scored in those with NAFLD to measure the risk of advanced liver fibrosis.
Results:
Prevalence of NAFLD was greater in patients with psoriasis than in controls (44% vs. 26%, P < 0.001). NAFLD-FS was higher in patients with psoriasis than in controls, suggesting a higher risk of liver fibrosis in those with psoriasis (-1.57 ± 1.4 vs. -3.10 ± 1.5, mean ± SD, P < 0.0001). Psoriasis resulted in a significant predictor of advanced liver fibrosis independently of age, sex, BMI, hypertension and diabetes in the multivariate analysis.
Conclusions:
Patients with psoriasis should be screened for common causes of liver disease, including NAFLD and liver fibrosis.
Related Concept Videos
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test